Crystagen

Last Updated: May 2026

Crystagen is a synthetic tripeptide (Glu-Asp-Pro) from the Khavinson bioregulator family, researched for thymic-tissue-targeted bioregulation, immune system function, and T-cell-derived cellular activity. It is one of the synthesized Khavinson compounds with a defined three-amino-acid sequence and overlaps in functional positioning with Thymalin (the polypeptide thymic extract). Crystagen is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.

What is Crystagen and how does the thymic bioregulatory mechanism work?

Crystagen is a synthetic Glu-Asp-Pro tripeptide proposed to enter thymic-tissue cell nuclei and modulate gene expression in pathways related to T-cell maturation, immune regulation, and thymic function. Within the Khavinson framework, Crystagen is the synthesized single-sequence complement to Thymalin (the polypeptide thymic extract), with both targeting immune function but through different molecular forms — Crystagen as a defined tripeptide, Thymalin as a multi-component extract. Preclinical work has reported effects on T-cell function markers and immune regulation parameters. Evidence level: Preclinical (cell culture, rodent); Khavinson-group research; independent replication limited.

What does the research show for Crystagen?

Preclinical studies from the Khavinson group have reported effects on T-cell function markers, lymphocyte populations, and immune regulation parameters in cell culture and rodent models. Human clinical research has been conducted in Russian contexts as part of broader bioregulator protocols, often in combination with Thymalin and other immune-targeted bioregulators. FDA-grade Phase 2/3 standards have not been applied. Evidence level: Preclinical; Khavinson-group research; FDA-grade Phase 2/3 not conducted.

How does Crystagen compare to other Khavinson immune-targeted bioregulators?

Crystagen sits in the immune-targeting subset alongside Thymalin (polypeptide extract) and Vilon (dipeptide), with the three compounds proposed to act on overlapping but distinct aspects of immune function.

What are the documented side effects of Crystagen?

Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards. Evidence level: Preclinical safety; human long-term unestablished.

What is the regulatory status of Crystagen?

Crystagen is not approved by the FDA, EMA, or any major Western regulator as of May 2026. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Why does Crystagen vendor verification matter?

Crystagen's short tripeptide structure (Glu-Asp-Pro) makes synthesis straightforward, but identity verification requires mass spectrometry confirmation to distinguish from related Khavinson tripeptides and ensure correct sequence. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Crystagen vendors?

Peptigrity purchases Crystagen vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.

Frequently Asked Questions

What does Crystagen do?

Crystagen is proposed to act on thymic and T-cell function through epigenetic gene-expression modulation, with preclinical research focused on immune regulation markers. Human Phase 2/3 efficacy is not established at Western clinical standards.

How does Crystagen differ from Thymalin?

Crystagen is a synthesized single-sequence tripeptide (Glu-Asp-Pro); Thymalin is a polypeptide extract from bovine thymus tissue containing multiple constituent peptides. Crystagen is more standardizable and easier to characterize; Thymalin has the Russian clinical-practice approval and longer human-use track record.

Is Crystagen legal to purchase?

Crystagen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Crystagen be FDA-approved?

No active FDA approval pathway exists for Crystagen as of May 2026.

How can I verify a Crystagen vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Crystagen dose?

No. Crystagen is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Crystagen is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.